Abstract 376P
Background
Optimal treatment outcomes in breast cancer heavily rely on patient adherence to oral anticancer medications (OAMs). This study investigates the differences in adherence rates between metastatic and non-metastatic breast cancer patients using a comprehensive dual-method approach.
Methods
In this cross-sectional study at the National Cancer Institute, Cairo University, 500 breast cancer patients were categorized into metastatic (45.6%) and non-metastatic (54.4%) groups. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8) and the Medication Possession Ratio (MPR), with nonadherence defined as an MMAS-8 score < 8 or an MPR < 80 %. Data collection was augmented by patient interviews and examination of outpatient pharmacy dispensing records.
Results
Adherence rates were 46.4% as per MMAS-8 and 71% according to MPR. Specifically, in the non-metastatic group, MMAS-8 revealed a 28.3% adherence rate, while MPR showed 75.4%. Metastatic patients displayed significantly higher adherence (p<0.001). There was a notable inverse correlation between adherence and the severity of side effects like musculoskeletal pain, neurological symptoms, fatigue, and hot flushes (p<0.001). Additionally, adherence varied with treatment duration, with shorter periods associated with better adherence.
Conclusions
The study confirms that adherence to OAMs is significantly affected by both the metastatic status and the severity of side effects. It highlights the urgent need for enhanced educational and management strategies tailored to the specific challenges faced by breast cancer patients, especially those dealing with severe side effects. Ongoing research should focus on developing and testing targeted interventions to improve adherence in these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Institute, Cairo University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
404P - Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 15
405P - HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Presenter: Violeta Serra
Session: Poster session 15
406P - Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Presenter: Abeid Omar
Session: Poster session 15
407P - Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer
Presenter: Xuenan Peng
Session: Poster session 15
408P - Characterizing the genomic landscape of breast cancer in an Irish cohort of patients
Presenter: Georgia Thodi
Session: Poster session 15
409P - Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Presenter: Jo De Vos
Session: Poster session 15
410P - Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Presenter: Angela Margarida Nogal Dias
Session: Poster session 15
412P - Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Presenter: Hope Rugo
Session: Poster session 15
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15